| Characteristic | N = 614 |
| --- | --- |
| **Gender, n (%)** |  |
| *Male* | 359 (58) |
| *Female* | 255 (42) |
| **Age at 1st Treatment** |  |
| *Median (IQR)* | 71 (60, 78) |
| *(Missing)* | 0 (0%) |
| **BRAF status, n (%)** |  |
| *Wild-type* | 301 (49) |
| *Mutant* | 296 (48) |
| *(Missing)* | 17 (2.8) |
| **First-line treatments, n (%)** |  |
| *No treatment* | 102 (17) |
| *Anti-PD-1* | 306 (50) |
| *Anti-PD-1 plus Anti-CTLA-4* | 90 (15) |
| *BRAFi* | 116 (19) |
| **CNS metastases, n (%)** | 148 (24) |
| **Disease stage, n (%)** |  |
| *M1c/M1d* | 393 (64) |
| *III/M1a/M1b* | 221 (36) |
| **LDH level** |  |
| *Median (IQR)* | 212 (176, 282) |
| *(Missing)* | 46 (7.5%) |
| **Performance status, n (%)** |  |
| *0/1* | 440 (72) |
| *2/3/4* | 164 (27) |
| *(Missing)* | 10 (1.6) |
| **Immunosuppressive medications, n (%)** | 105 (17) |
| **Comorbidities, n (%)** | 92 (15) |
| **Autoimmunity, n (%)** | 54 (8.8) |
| **Other malignancies, n (%)** | 63 (10) |